7 min ago
The Beaumont Enterprise
Merck 2Q profit more than doubles
In this Thursday, Feb. 28, 2013 photo, Merck scientist Pascale Nantermet conducts research to discover new HIV drugs in West Point, Pa.
Fri Jul 25, 2014
Merck to cut 600 jobs in Montco
Merck & Co., which is reorganizing to slash $2.5 billion in costs and 8,500 workers, has informed Pennsylvania officials that it will cut 600 jobs at facilities in North Wales and Lansdale.
Thu Jul 24, 2014
Merck Looks Overpriced Compared To This Sector Peer
We pitch two companies from the pharmaceutical sector, Merck and AbbVie, against one another in the latest installment of our Head-To-Head series.
Wed Jul 23, 2014
IPR Update -- The First Pharma IPR Decisions
Late last month, while many of us were getting ready to attend the BIO International Convention in San Diego, the Patent Trial and Appeal Board issued four related inter partes review opinions, marking what many have called the first set of opinions related to the Pharmaceutical industry.
Biopharma industry at highest risk for employee turnover
A new survey reveals it might be easier for companies in the biopharma industry to poach employees from one another, especially among employees who view themselves as underpaid.
Wed Jul 16, 2014
Strides Arcolab Makes Strategic Investment In Oncobiologics Inc., USA
Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc., a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.
Mon Jul 14, 2014
Merck KGaA Appoints New Global Head Of R&D For Biopharma Division
Merck KGaA's biopharmaceutical division today announced the appointment of Luciano Rossetti, M.D., as Executive Vice President and Global Head of Research & Development as of July 21, 2014.
Tue Jul 08, 2014
Merck & Co. PT Raised to $60.00
Leerink Swann's target price suggests a potential upside of 3.15% from the company's current price.
Mon Jun 30, 2014
Merck & Co., Inc.'s Pediatric Anti-Vomiting Drug Effective In Phase 3 Trial
Merck Announces Data from Investigational Phase 3 Study on EMENDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Children Undergoing Emetogenic Chemotherapy Merck Planning Regulatory Submissions in the U.S. for EMENDA in Pediatric Setting Including New Suspension Formulation in Second Half of 2014 WHITEHOUSE STATION, N.J.-- ... (more)